Cite
HARVARD Citation
Argiles, G. et al. (n.d.). O-026Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Annals of oncology. p. . [Online].